Unraveling the potential biomarkers of immune checkpoint inhibitors in advanced ovarian cancer: a comprehensive review

被引：1
|
作者：
Na, Jian-rong [1 ]
Liu, Yaqin [2 ]
Fang, Kun [3 ]
Tan, Yuan [2 ]
Liang, Pan-pan [4 ]
Yan, Mei [5 ]
Chu, Jiao-jiao [5 ]
Gao, Jian-mei [5 ]
Chen, Dongsheng [2 ,6 ,7 ]
Zhang, Shu-xiang [1 ]
机构：
[1] Ningxia Med Univ, Clin Coll 1, Dept Resp & Crit Care Med, Yinchuan 750004, Peoples R China
[2] Nanjing Simcere Med Lab Sci Co Ltd, Jiangsu Simcere Diagnost Co Ltd, State Key Lab Neurol & Oncol Drug Dev, Nanjing 210002, Peoples R China
[3] Yinchuan Maternal & Child Hlth Hosp, Yinchuan 750004, Peoples R China
[4] Peoples Hosp Ningxia Hui Autonomous Reg, Yinchuan 750004, Peoples R China
[5] Ningxia Med Univ, Gen Hosp, Yinchuan 750004, Peoples R China
[6] Jinzhou Med Univ, Affiliated Hosp 1, Canc Ctr, Jinzhou, Peoples R China
[7] Jinzhou Med Univ, Affiliated Hosp 1, Ctr Translat Med, Jinzhou, Peoples R China
来源：
INVESTIGATIONAL NEW DRUGS | 2024年 / 42卷 / 06期
关键词：
Ovarian cancer; Immunotherapy; Biomarkers; Genomics; Transcriptomics; Proteomics; PREDICTIVE BIOMARKERS; PLATINUM-RESISTANT; IMMUNOTHERAPY; PEMBROLIZUMAB; COMBINATION;
D O I：
10.1007/s10637-024-01478-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The ongoing research on the role of immunotherapy in advanced ovarian cancer (OC) and current clinical trials indicate that patients shown limited response to immune checkpoint inhibitor (ICI) monotherapy. When combined with other treatments or drugs, the efficacy of immunotherapy will be significantly improved. Biomarkers can be used to identify patients with better responses, thereby improving the precision and efficacy of immunotherapy. Key biomarkers for advanced OC include homologous repair deficiency, programmed death-ligand (PD-L) 1 expression, chemokines, and tumor infiltrating lymphocytes. These biomarkers could be applied in the future to select the most suitable patient populations. This review comprehensively examines the research and development of biomarkers in OC immunotherapy from three omics perspectives: genomics, transcriptomics, and proteomics, which may provide guidance for the effectiveness of OC immunotherapy strategies.
引用
收藏
页码：728 / 738
页数：11
相关论文
共 50 条
  • [21] Clinical outcome of sequential chemotherapy after immune checkpoint inhibitors in advanced ovarian cancer.
    Bonilla, Luisa
    Oza, Amit M.
    Lheureux, Stephanie
    Saibil, Sam
    Chen, Shiyi
    Lee, Yeh Chen
    Gray, Diana
    Colombo, Ilaria
    Madariaga, Ainhoa
    Dhani, Neesha C.
    Bhat, Gita
    Bowering, Valerie
    Garg, Swati
    Yokom, Daniel
    Cyriac, Sunu Lazar
    Butler, Marcus O.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [22] Uncovering the flip side of immune checkpoint inhibitors: a comprehensive review of immune-related adverse events and predictive biomarkers
    Miao, Yan-Dong
    Quan, Wu-Xia
    Tang, Xiao-Long
    Shi, Wei-Wei
    Li, Qing
    Li, Rui Jian
    Wang, Jiang-Tao
    Gan, Jian
    Dong, Xin
    Hao, Liang
    Luan, Wen-Yu
    Zhang, Fang
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2024, 20 (02): : 621 - 642
  • [23] Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer
    Sivapiragasam, Abirami
    Kumar, Prashanth Ashok
    Sokol, Ethan S.
    Albacker, Lee A.
    Killian, Jonathan K.
    Ramkissoon, Shakti H.
    Huang, Richard S. P.
    Severson, Eric A.
    Brown, Charlotte A.
    Danziger, Natalie
    McGregor, Kimberly
    Ross, Jeffrey S.
    CANCER MEDICINE, 2021, 10 (01): : 53 - 61
  • [24] Predictive biomarkers for immune checkpoint inhibitors therapy in lung cancer
    Yao, Jie
    Lin, Xuwen
    Zhang, Xin
    Xie, Mei
    Ma, Xidong
    Bao, Xinyu
    Song, Jialin
    Liang, Yiran
    Wang, Qiqi
    Xue, Xinying
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)
  • [25] Comprehensive assessment of multiple tryptophan metabolites as potential biomarkers for immune checkpoint inhibitors in patients with non-small cell lung cancer
    M. Karayama
    J. Masuda
    K. Mori
    H. Yasui
    H. Hozumi
    Y. Suzuki
    K. Furuhashi
    T. Fujisawa
    N. Enomoto
    Y. Nakamura
    N. Inui
    T. Suda
    M. Maekawa
    H. Sugimura
    A. Takada
    Clinical and Translational Oncology, 2021, 23 : 418 - 423
  • [26] Comprehensive assessment of multiple tryptophan metabolites as potential biomarkers for immune checkpoint inhibitors in patients with non-small cell lung cancer
    Karayama, M.
    Masuda, J.
    Mori, K.
    Yasui, H.
    Hozumi, H.
    Suzuki, Y.
    Furuhashi, K.
    Fujisawa, T.
    Enomoto, N.
    Nakamura, Y.
    Inui, N.
    Suda, T.
    Maekawa, M.
    Sugimura, H.
    Takada, A.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2021, 23 (02): : 418 - 423
  • [27] Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer
    Lorusso, Domenica
    Ceni, Valentina
    Muratore, Margherita
    Salutari, Vanda
    Nero, Camilla
    Pietragalla, Antonella
    Ciccarone, Francesca
    Carbone, Vittoria
    Daniele, Gennaro
    Scambia, Giovanni
    EXPERT OPINION ON EMERGING DRUGS, 2020, 25 (04) : 445 - 453
  • [28] Biomarkers for immune checkpoint inhibitors Reply
    Calabro, Luana
    Maio, Michele
    LANCET ONCOLOGY, 2014, 15 (01): : E1 - E2
  • [29] Bibliometric and visual analysis of immune checkpoint inhibitors for ovarian cancer
    Meng, Shunyao
    Song, Shiyi
    Yin, Rutie
    ASIAN JOURNAL OF SURGERY, 2024, 47 (07) : 3205 - 3206
  • [30] Biomarkers for immune Checkpoint inhibitors in Melanoma
    Kitano, Shigehisa
    Nakayama, Takayuki
    Yamashita, Makiko
    FRONTIERS IN ONCOLOGY, 2018, 8
12345